We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

GEMS platform

Advertisement

cGxPJobs Banner

Incyte Expands AI Drug Discovery With Genesis

WILMINGTON, Del. & SAN MATEO, Calif., May 20, 2026 Incyte and Genesis Molecular AI have announced a significant expansion...

By cGxPwire Editor
May 22, 2026

Read More

Advertisement

cGxPJobs

Recent Posts

01

.Clinical

Otsuka Reports Final Phase 3 VOYXACT Results in IgA Nephropathy
October 24, 2026
02

MedTech

Fresenius Launches multiFiltratePRO for Critical Kidney Care
October 24, 2026
03

.Tech

Genialis Demonstrates Biology-First AI in Cancer Research
October 24, 2026
04

.Clinical

Alnylam Reports Positive Phase 1b Data for Brezosiran in Huntington’s Disease
October 24, 2026
05

.Clinical

Summit Therapeutics and Lunit Partner on AI Cancer Research
October 24, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website